Target on molecular therapies in lung cancer;Thérapeutiques moléculaires ciblées en cancérologie bronchique

Bulletin du Cancer

Volumn 90, Issue 12, 2003, Pages 1055-1061

  Le Guen, Yannick ^a   Sabatier, Laure ^b   Le Chevalier, Thierry ^a   Soria, Jean Charles ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

Angiogenesis; C kit; EGFR; Lung cancer; Molecular target; Molecular therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AE 941; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEXAROTENE; BMS 27529; BORTEZOMIB; CANERTINIB; CARBOPLATIN; CC 1779; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; EXSULIND; FENRETINIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; IMATINIB; ISIS 3521; LONAFARNIB; MARIMASTAT; NAVELBINE; OBLIMERSEN; PACLITAXEL; PRINOMASTAT; SEMAXANIB; STEM CELL FACTOR; TACROLIMUS; TAXANE DERIVATIVE; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CLINICAL TRIAL; HUMAN; LUNG CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 0742269820     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Arriagada R, Le Chevalier T, Pignon JP, Riviète A, Monnet I, Chomy P, et al. Initial chemotherapeutic doses and survival in patients with limited small cell lung cancer. N Engl J Med 1993 ; 329 : 1848-52.
2. Pujol JL, Dautes JP, Riviète A, Quoix E, Westeel V, Quantin X, et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small cell lung cancer : a French federation of cancer institutes multicenter phase III randomized study. J Natl Cancer Inst 2001 ; 93 : 300-8.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 ; 346 : 92-8.
4. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer : seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996 ; 88 : 1210-5.
5. Le Chevaliet T, Atriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small-cell lung cancer : first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991 ; 83 : 417-23.
6. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002 ; 20 : 247-53.
7. Giaccone G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M et al. A phase III clinical trial of ZD 1839 (Iressa), in combination with gemcitabine and cisplatin in chemotherapy naive patients with advanced non small cell lung cancer (Intact 1). Ann Oncol 2002 ; 13 (suppl.) : 2.
8. Johnson DH, Herbst R, Giaccone G, Sciller J, Natale RB, Miller V, et al. ZD 1839 (Iressa), in combination with paclitaxel and carboplatin in chemotherapy naive patients with advanced non small cell lung cancer (NSCLC) : results from a phase III clinical trial (Intact 2). Ann Oncol 2002 ; 13 (suppl.) : 127.
9. Johnson BE, Fisher B, Fisher T, Dunlop D, Rischin D, Silberman S, et al. Phase II study of STI571 (Gleevec) for patients with small cell lung cancer. Proc Am Soc Clin Oncol 2002 ; 21 : 293a.
10. Smylie M, Mercier R, Aboulafia D, Tucker R, Bonomi P, Collier M, et al. Phase III of the matrix metalloprotease (MMP) inhibitor Prinomastat in patients having advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001 ; 20 : 307a.
11. Bissett D, O'Byrne KJ, von Pawel J, Mercier R, Price A, Nicolson M, et al. Phase III of the matrix metalloprotease (MMP) inhibitor Prinomasrat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002 ; 21 : 296a.
12. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, et al. Prospective, randomized, double-blind, placebo-controlled trial of Marimastat after response to first line chemotherapy in patients with small cell lung cancer. A trial of the National cancer institute of Canada-clinical trials group and the European organization for research and treatmenr of cancer. J Clin Oncol 2002 ; 20 : 4434-9.
13. Hanahan D, Weinberg A. The hallmarks of cancer. Cell 2000 ; 100 : 57-70.
14. Meric JB, Faivre S, Monnerat C, Adi Vago N, Le Chevalier T, Armand JP, Raymond E. Zd 1839 «Iressa». Bull Cancer 2000 ; 87 : 873-6.
15. Azzoli CG, Krug LM, Miller VA, Kris MG, Mass R. Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol 2002 ; 29 (suppl.) : 59-65.
16. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment : the emerging role of IMC-C225 in the treatment of lung and head and necks cancers. Semin Oncol 2002 ; 29 (suppl.) : 27-36.
17. Langer CJ, Adak S, Thot A, Vangel M, Johnson D. Phase II Eastern cooperative oncology group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu(+) advanced non small cell lung cancer (NSCLC) : early analysis of E2598. Proc Am Soc Clin Oncol 2001 ; 20 : 315a.
18. Krug LM, Millet VA, Crapanzano J, Ng KK, Pizzo B, Tyson L, et al. Randomized phase II trial of trastuzumab (tras) plus either weekly docetaxel (doc) or paclitaxel (pac) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001 ; 20 : 333a.
19. Zinner RG, Glisson BS, Pisyets KM, Khuri FR, Oh YW, Ro NG, et al. Cisplatin and gemcitabin combined with hetceptin in patients with HER2 overexpressing, untreated, advanced, non-small cell lung cancer : a phase II trial. Proc Am Soc Clin Oncol 2001 ; 20 : 328a.
20. Gatzmeiet U, Groth G, Hitsh V, Butts CA, Van Zandwijk N, Shephetd F, et al. Gemcitabine/cisplacin alone and with trastuzumab (Hetceptin) in patients with non small cell lung cancer overexpressing HER2 : results of randomised phase II study. Proc Am Soc Clin Oncol 2002 ; 21 : 297a.
21. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of geftinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2000 ; 21 : 2237-46.
22. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. A phase II trial of ZD 1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who have failled platinium and docetaxel-based regimens (Ideal2). Proc Am Soc Clin Oncol 2002 ; 21 : 292a.
23. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinium-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002 ; 21 : 310a.
24. Inoue A, Sajio Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and geftinib. Lancet 2003 ; 361 : 137-9.
25. Lyod KP, Krystal GW. Role of small-molecule Kit receptor tyrosine kinase inhibitors in the treatment of small-cell lung cancer. Clin Lung Cancer 2002 ; 3 : 213-8.
26. Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 1994 ; 13 : 411-31.
27. Yuen A, Hasley J, Fisher G, Advani R, Moore M, Saleh M, et al. Phase I/ II of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 2001 ; 20 : 309a.
28. Moore MR, Saleh M, Jones CM, Irwin D, Gervais R, Kerr R, et al. Phase II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha, with docetaxel in non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002 ; 21 : 297a.
29. Flaherty KT, Stevenson JP, O'Dwyer PJ. Antisense therapeutics : lessons from early trials. Curr Opin Oncol 2001 ; 13 : 499-505.
30. Perrin D, Halazy S, Hill B. Inhibitors of Ras farnesylation : tomorrow's anticancer agents ? Bull Cancer, 1997 ; 84 : 635-42.
31. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increasead prevalence of k-ras oncogene in lung adenocarcinoma. Cancer Res 1995 ; 55 : 1444-7.
32. Adjei AA, Mauer A, Marks R, Hillman S, Bruzek LM, Geyer S, et al. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2002 ; 21 : 290a.
33. Huang S, Houghton PJ. Resistance to rapamycin : a novel anticancer drug. Cancer Metastasis Rev 2001 ; 20 : 69-78.
34. Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 2001 ; 19 : 2626-37.
35. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001 ; 7 : 1590-9.
36. Bunn P, Chan D, Earle K, Zhao T, Helfrich B, Kelly K, et al. Preclinical and clinical studies of docetaxel and exsulind in the treatment of human lung cancer. Semin Oncol 2002 ; 29 (suppl.) : 87-94.
37. Rudin CM, Otterson GA, Mauer AM, Villalona-Caleto MA, Tomek R, Ptange B, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemotefractory small-cell lung cancer. Ann Oncol 2002 ; 13 : 539-45.
38. Murray RZ, Norbury C. Proteasome inhibitors as anti-cancer agents. Anti-Cancer Drugs 2000 ; 11 : 407-17.
39. Aghajanian C, Soignet S, Dizon DS, Pien CS; Adams J, Elliott PJ, et al. A phase I of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002 ; 8 : 2505-11.
40. Folkman J. What is the evidence that tumors are angiogenesis dependant ? J Natl Cancer Inst 1990 ; 82 : 4-6.
41. Brechot JM, Dinh X. Angiogenèse et cancer bronchique : une nouvelle cible thérapeutique. Rev Mal Respir 2000 ; 17 : 381-8.
42. Herbst RS, Hildago M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol 2002 ; 29 (suppl): 66-77.
43. DeVore RF, Fehrenbacher L, Herbst RS, Langer CJ, Kelly K, Gaudreault J, et al. A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000 ; 19 : 485a.
44. Dy GK, Adjei AA. Novel targets for lung cancer : part II. J Clin Oncol 2002 ; 20 : 3016-28.
45. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors : evidence for activity in non-small cell lung cancer. J Clin Oncol 2002 ; 20 : 4440-7.
46. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occuring multifunctional antiangiogenic drug in phase III clinical trials. Semin Oncol 2001 ; 28 : 620-5.
47. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000 ; 19 : 3460-9.
48. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 ; 34 : 783-92.
49. Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targered therapies : implications for drug development and practice. Clin Cancer Res 2003 9 : 1579-89.
50. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial c9741/cancer and leukemia group B trial 9741. J Clin Oncol 2003 ; 21 : 1431-9.
51. Piccart M, Dochy E, Cardoso F. Actualités thérapeutiques dans le traitement médical du cancer du sein. Bull Cancer 2003 ; 90 : 46-52.
52. Gumerlock PH, Kawaguchi T, Moisan LP, Lau AH, Mack PC, Lara PN, et al. Mechanisms of enhanced cytotoxicity from docetaxel-PS341 combination in non small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 2002 ; 21 : 304a.
53. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, Milano G. Sequence-dependent effects of ZD1839 (Iressa) in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002 ; 86 : 819-27.
54. Dy GK, Adjei AA. Novel targets for lung cancer : part I. J Clin Oncol 2002 ; 20 : 2881-94.